Active Biotech AB Receives Tasquinimod Milestone Payment From Ipsen for 10TASQ10 Study

Published: Oct 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Active Biotech, under the terms of the co-development and commercialization agreement on the novel candidate drug tasquinimod, has received a milestone payment of 12 million euros from Ipsen.

Help employers find you! Check out all the jobs and post your resume.

Back to news